AFI-D2 forte

Hypoparathyroidism, pseudohypoparathyroidism, tetany, bone diseases caused by vitamin D deficiency.

The drug is indicated for use in Rh-negative women who are not sensitized to the Rh0(D) antigen (i.e., in the absence of Rh antibodies), provided that:

pregnancy and birth of a rh-positive child,

with artificial and spontaneous abortion,

when aborting an ectopic pregnancy,

at the threat of termination of pregnancy at any time,

after performing an amniocentesis and other procedures associated with the risk of fetal blood entering the mother's bloodstream, as well as when receiving an abdominal injury.

Hypoparathyroidism (idiopathic or postoperative), pseudohypoparathyroidism.

Inside, on an empty stomach or after eating with a small amount of liquid, you can-with food (for example, on a piece of bread or sugar), the oil solution does not mix with water.

The daily dose is determined by the doctor individually, depending on the level of calcium in the blood.

0.5 mg of the drug AFI-D2 forte^® corresponds to about 15 drops.

Recommended doses: in hypoparathyroidism-0.75-2.5 mg/day for several days, the maintenance dose-0.2-1 mg / day.

The daily dose of the drug can be taken in several doses. The duration of treatment is determined by the doctor.

Treatment with AFI - D2 forte^® you can't interrupt it yourself.

In/m. 1 dose (1500 IU) or 2 doses (3000 IU) once: to the mother — within 72 hours after delivery, in case of termination of pregnancy — immediately after the end of the operation.

The following criteria must be met:

- the mother must be Rh-negative and not already sensitized to the Rh0(D) factor.),

"her baby must be Rh-positive.

If the drug is administered before delivery, it is important that the mother receives another 1 dose of the drug after the birth of a Rh-positive child within 72 hours after delivery. If it is established that the father is Rh-negative, there is no need to administer the drug.

Before administration, the syringes with the drug are kept for 2 hours at room temperature (20±2 °C). In order to avoid the formation of foam, the drug is typed into the syringe with a needle with a wide lumen.

The drug can not be administered in/in!

For prevention in the postpartum period 1 dose (1500 IU) of AFI-D2 forte should be administered within the first 72 hours after delivery. The need for a certain dose in the case of passing the full term of pregnancy is different depending on the volume of fetal blood that has entered the mother's bloodstream. 1 dose (1500 IU) contains a sufficient amount of antibodies to prevent sensitization to the Rh factor, if the volume of fetal red blood cells entering the bloodstream does not exceed 15 ml. In cases where a larger volume of fetal red blood cells is expected to enter the mother's bloodstream (more than 30 ml of whole blood or more than 15 ml of red blood cells), the fetal red blood cells should be counted using an approved laboratory technique (for example, the modified Kleihauer and Betke acid wash-staining method) to determine the required dose of the drug. The calculated volume of fetal red blood cells that have entered the mother's bloodstream is divided by 15 ml and the number of doses of AFI-D2 forte to be administered is obtained. If the presence of more than 15 ml of fetal red blood cells is assumed or a fractional number is obtained as a result of dose calculations, the number of doses should be rounded up to the next integer in the upward direction, for example, when obtaining the result of 1.4, 2 doses (3000 IU) of the drug should be administered

For prevention in the prenatal period 1 dose of the drug (1500 IU) should be administered approximately at the 28th week of pregnancy. Then it is necessary to introduce another 1 dose (1500 IU), preferably within 72 hours after delivery, if the child is born Rh-positive.

In the case of continued pregnancy after the threat of abortion at any time of pregnancy, you should enter 1 dose (1500 IU) of the drug. If more than 15 ml of fetal red blood cells are suspected of entering the mother's bloodstream, the dose should be changed (as indicated above).

After a spontaneous abortion, artificial abortion, or termination of an ectopic pregnancy with a gestation period of more than 13 weeks It is recommended to administer 1 dose (1500 IU) of the drug. If more than 15 ml of fetal red blood cells are suspected of entering the mother's bloodstream, the dose should be changed (as indicated above). If the pregnancy is terminated at less than 13 weeks, a single administration of a mini-dose of AFI-D2 forte (approximately 250 IU) is possible.

After performing an amniocentesis at 15-18 weeks of pregnancy or during the third trimester of pregnancy, or after receiving an abdominal injury during the second and / or third trimester of pregnancy you should enter 1 dose (1500 IU) of the drug. If more than 15 ml of red blood cells are suspected of entering the mother's bloodstream, the dose should be changed as described above. If an abdominal injury, amniocentesis, or other adverse event requires the administration of the drug at the period of 13-18 weeks of pregnancy, another 1 dose (1500 IU) should be administered at the period of 26-28 weeks.

To maintain protection throughout pregnancy, the concentration of passively obtained Rh0(D) antibodies should not fall below the level necessary to prevent an immune response to Rh-positive red blood cells. T_1/2 human immunoglobulin antiresus Rh0 (D) is 23-26 days old. In any case, the dose of the drug should be administered within 72 hours after delivery, if the child is Rh-positive. If the delivery occurs within 3 weeks after receiving the last dose, the postpartum dose can be canceled (except in cases where more than 15 ml of fetal red blood cells have entered the mother's bloodstream).

Inside, after a meal or on an empty stomach, with a small amount of liquid (high doses are mixed with food). The doses are set individually (depending on the content of calcium in the blood serum). Usually the daily dose is 0.5-1.5 mg (corresponding to 12-36 drops).

Hypercalcemia, carbon dioxide poisoning, tetanic seizures.

hypersensitivity to the drug,

rh-positive maternity hospitals,

Rh-negative women in childbirth, sensitized to the Rh0(D) antigen (in the blood serum of which Rh antibodies were found).

It is forbidden to administer the drug to newborns.

Hypercalcemia, overdose of vitamin D preparations.

Hypercalcemia, loss of appetite, dyspeptic disorders, increased fatigue, thirst, headache, polyuria, calcium deposition in the tissues (calcification).

Possible: hyperemia, an increase in body temperature to 37.5° (during the first day after administration), dyspeptic phenomena.

In some cases - patients with altered reactivity (including immunoglobulin A deficiency) may develop allergic reactions of various types (including anaphylactic shock).

Hypercalcemia (lack of appetite, nausea, vomiting, diarrhea, pallor, headaches, palpitations, thirst, with prolonged hypercalcemia-impaired renal function, cardiosclerosis, pneumosclerosis, nephrosclerosis), dyspepsia.

• Regulator of calcium and phosphorus metabolism [Correctors of bone and cartilage tissue metabolism]
• Vitamins and vitamin-like products

• Immunoglobulins

• Correctors of bone and cartilage metabolism
• Vitamins and vitamin-like products

It is incompatible with calcium preparations, parathyroid hormone, some diuretics, vitamin D and similar substances.

The drug interaction of AFI-D2 forte is not described.

Incompatible with vitamin D preparations. Hypercalcemia may be enhanced by thiazides, thyroxine withdrawal.